文献速递膀胱癌与上尿路尿路上皮癌

BCG诱导后免疫标志物对膀胱癌治疗结局的预测价值

Predictive value of immunological markers after bacille Calmette-Guérin induction in bladder cancer.
PubMed 文献 · BJU Int · 2021-09-13

该研究纳入204例高危非肌层浸润性膀胱癌患者,在BCG诱导前后检测尿液和血液免疫标志物。尿IL-10和血清TNF-α可显著预测初始完全缓解,尿IL-10、血清CTLA-4、TFs及GATA3+/T-bet+比值的变化模式可独立预测复发和进展。

要点

  • 尿IL-10和血清TNF-α变化可预测BCG诱导后初始完全缓解。
  • 尿IL-10、血清CTLA-4、TFs变化模式及GATA3+/T-bet+比值可预测复发。
  • 上述标志物可独立预测肿瘤进展,辅助临床决策。

核心结论

  • 尿IL-10和血清TNF-α可显著预测初始完全缓解。
  • BCG诱导后尿IL-10、血清CTLA-4、转录因子及GATA3+/T-bet+比值变化模式可独立预测后续BCG反应。

研究设计与样本

  • 前瞻性研究纳入204例接受经尿道膀胱肿瘤电切术的高危NMIBC患者。
  • 在基线(首次诱导剂量前)和诱导后(第六次剂量后4小时)采集尿液和血液样本。
  • 尿液用固相酶联免疫吸附试验检测IL-2和IL-10,血液用定量RT-PCR检测TNF-α、CTLA-4及转录因子GATA3、T-bet、FoxP3。

主要发现

  • 尿IL-2和血清TNF-α在所有患者中升高;血清CTLA-4和FoxP3+分别有188例(92.2%)和192例(94.1%)呈优势降低模式。
  • 186例(91.2%)达到初始完全缓解;中位随访37(20-88)个月,104例(56%)复发,34例(18.3%)进展。
  • 血清TNF-α倍数变化和尿IL-10变化模式与初始完全缓解显著相关(P=0.001和P=0.03)。
  • 尿IL-10、血清CTLA-4、T-bet+、FoxP3+变化模式及GATA3+/T-bet+比值与复发显著相关(P=0.001、P=0.001、P=0.02、P=0.009和P=0.001)。
  • 尿IL-10、血清CTLA-4、血清T-bet+变化模式及GATA3+/T-bet+比值是肿瘤进展的独立预测因素(P=0.001、P=0.001、P=0.02和P=0.001)。

临床怎么用

  • 这些标志物可用于讨论管理方案时或BCG严重短缺的系统中辅助临床决策。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: To investigate the predictive value of different immunological markers on treatment outcomes after bacille Calmette-Guérin (BCG) induction in high-risk non-muscle-invasive bladder cancer (NMIBC). PATIENTS AND METHODS: Patients who underwent transurethral resection of bladder tumour for NMIBC were assessed for study eligibility. Urine and blood samples were taken from patients at baseline (immediately before first dose of induction) and after induction (4 h after last [sixth] dose). Urine samples were evaluated for interleukin (IL)-2 and IL-10 by solid-phase enzyme-linked immunosorbent assay. Blood samples were evaluated for tumour necrosis factor α (TNF-α), cytotoxic T-lymphocyte antigen 4 (CTLA-4) and transcription factors (TFs) (GATA-binding protein 3 [GATA3], T-box expressed in T cells [T-bet], and forkhead box protein 3 [FoxP3]) using quantitative reverse transcriptase-polymerase chain reaction analysis. Change pattern and fold change of each evaluable marker was assessed in relation to different treatment outcomes (initial complete response [ICR]/recurrence/progression). RESULTS: Between July 2013 and May 2019, 204 patients were included. Among evaluable markers, urinary IL-2 and serum TNF-α increased in all patients, serum CTLA-4 and FoxP3+ showed a predominant decreased pattern in 188 (92.2%) and 192 (94.1%) patients, respectively. An ICR was achieved in 186 (91.2%) patients. Serum TNF-α fold change and urinary IL-10 change pattern were significantly associated with an ICR (P = 0.001 and P = 0.03, respectively). At a median (range) follow-up of 37 (20-88) months, 104 (56%) patients developed recurrence. Urinary IL-10, serum CTLA-4, T-bet+ , FoxP3+ change patterns and GATA3+ /T-bet+ ratio were significantly associated with tumour recurrence (P = 0.001, P = 0.001, P = 0.02, P = 0.009 and P = 0.001, respectively). Tumour progression occurred in 34 (18.3%) patients. Urinary IL-10, serum CTLA-4, serum T-bet+ change patterns and GATA3+ /T-bet+ ratio were independent predictors of tumour progression (P = 0.001, P = 0.001, P = 0.02 and P = 0.001, respectively). CONCLUSIONS: Urinary IL-10 and serum TNF-α can significantly predict ICR. Moreover, change pattern of urinary IL-10, serum CTLA-4, TFs (GATA3, T-bet and FoxP3) and GATA3+ /T-bet+ ratio after BCG induction can independently predict further BCG response. These markers could be implemented in clinical practice when management options are discussed or in systems with severe BCG shortage.

来源:BJU Int,查看原文。版权归原作者所有。

引用

  1. Elsawy AA, Abol-Enein H, Laymon M, et al. Predictive value of immunological markers after bacille Calmette-Guérin induction in bladder cancer. BJU Int. 2021. PMID: 34448522. doi:10.1111/bju.15582

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。